Virax Biolabs Group Ltd

Virax Biolabs Group Ltd is a biotechnology company focused on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases. Incorporated in the Cayman Islands as an exempted holding company, Virax Biolabs Group Ltd conducts substantially all of its operations through subsidiaries located in the United Kingdom, the United States, and China. The company commenced operations in 2013. Its current strategic focus is on post-acute infection syndromes ("PAIS") and related areas of chronic immune dysfunction, with principal development activities centered on T cell-based immune profiling and in vitro diagnostics. Virax Biolabs Group Ltd's business is focused on two principal platforms: ViraxImmune and ImmuneSelect. ViraxImmune is the lead in-development T cell-based immune profiling and diagnostic platform, intended to measure and characterize T cell immune responses and other markers of immune dysfunction. Its initial clinical focus is on PAIS, including Long COVID, myalgic encephalomyelitis / chronic fatigue syndrome ("ME/CFS"), and post-treatment Lyme disease ("PTLD"). ImmuneSelect is a research-use-only ("RUO") portfolio comprising peptide pools, ELISpot plates, and related immune reagents. The company previously distributed third-party test kits under the ViraxClear and ViraxVet brands, which generated revenue in prior fiscal periods but are no longer active strategic product lines.